The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy

Li, Keting; Hao, Wentao; Liu, Xianben; Li, Yin; Sun, Haibo; Liu, Shilei; Xing, Wenqun; Zheng, Yan

doi:10.7150/jca.84484



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2023; 14(16):3130-3138. doi:10.7150/jca.84484 This issue Cite

Research Paper

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy

Keting Li, MD^1*, Wentao Hao, MD^1*, Xianben Liu, MD¹, Yin Li, MD, PhD^1,2, Haibo Sun, MD, PhD¹, Shilei Liu, MD¹, Wenqun Xing, MD¹, Yan Zheng, MD, PhD^1✉

1. Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China.
2. Department of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, BeiJing, China.
*These authors contributed equally to this work and share first authorship

Citation:

Li K, Hao W, Liu X, Li Y, Sun H, Liu S, Xing W, Zheng Y. The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy. J Cancer 2023; 14(16):3130-3138. doi:10.7150/jca.84484. https://www.jcancer.org/v14p3130.htm

Other styles

Abstract

Background: The aim of this study was to compare the efficacy of adjuvant chemotherapy after neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma (ESCC).

Methods: This retrospective study included patients diagnosed with ESCC at clinical stage T1N1-3M0 or T2-4N0-3M0. Six hundred and eleven patients underwent radical tumor surgical resection after neoadjuvant chemotherapy. Adjuvant chemotherapy was mainly a platinum-based combination regimen. Propensity score matching (PSM) was used to compare adjuvant chemotherapy (AC) vs. postoperative observation (POB) after surgery.

Results: A total of 611 patients were eligible, with 381 in the POB group and 230 in the AC group. POB group patients were younger (P=0.046) and at a later stage (ypT3/4: 127 [55%] vs. 177 [46%]), P=0.036; yPN+: 117[51%] vs. 3428[37%], P=0.001) before PSM. After 1:1 PSM, 213 pairs of patients were included in analysis. The 5-year overall survival (OS) was 60.6% and 57.2% in the POB and AC groups, respectively (HR 1.10, 95% CI: 0.80-1.51, P=0.562), and adjuvant chemotherapy did not improve OS compared with postoperative observation.

Conclusions: Postoperative adjuvant chemotherapy cannot improve the OS of patients with ESCC after neoadjuvant chemotherapy, but adjuvant chemotherapy tends to benefit ypN+ patients.

Keywords: esophageal squamous cell carcinoma, neoadjuvant chemotherapy, adjuvant chemotherapy, survival, prognosis.

Citation styles

APA

Li, K., Hao, W., Liu, X., Li, Y., Sun, H., Liu, S., Xing, W., Zheng, Y. (2023). The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy. Journal of Cancer, 14(16), 3130-3138. https://doi.org/10.7150/jca.84484.

ACS

Li, K.; Hao, W.; Liu, X.; Li, Y.; Sun, H.; Liu, S.; Xing, W.; Zheng, Y. The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy. J. Cancer 2023, 14 (16), 3130-3138. DOI: 10.7150/jca.84484.

NLM

CSE

Li K, Hao W, Liu X, Li Y, Sun H, Liu S, Xing W, Zheng Y. 2023. The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy. J Cancer. 14(16):3130-3138.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.